Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | ESRRG | P62508 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718186 | 0.82 | RCE1 (0.43) | RCE1MMP3HTR2AHTR2CSLC6A4 | |
| SCHEMBL1872003 | 0.74 | ALDH1A1 (0.35) | RCE1L3MBTL1CA12CA1CA2 | |
| SCHEMBL11898599 | 0.73 | MEN1 (0.46) | RCE1SIGMAR1MEN1KMT2AHTT | |
| SCHEMBL28028361 | 0.71 | RCE1 (0.47) | RCE1MEN1KMT2ACA12CA1 | |
| SCHEMBL28255833 | 0.68 | HSP90AA1 (0.50) | RCE1MMP3MEN1KMT2ACA12 | |
| SCHEMBL27857424 | 0.66 | CA1 (0.38) | SIGMAR1MEN1KMT2ACA1CA2 | |
| SCHEMBL4420650 | 0.65 | MEN1 (0.46) | HTR2AHTR2CSLC6A4SIGMAR1MEN1 | |
| SCHEMBL230197 | 0.65 | CTSK (0.36) | SIGMAR1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL23931825 | 0.64 | MEN1 (0.50) | MEN1KMT2AHTTL3MBTL1PYCR1 | |
| SCHEMBL6540918 | 0.64 | HDAC1 (0.51) | RCE1MEN1KMT2AL3MBTL1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323502-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOGEN MA INC. | 2014-10-30 | — | — | US | disclosed |
| US-20120322823-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. | 2012-12-20 | — | — | US | disclosed |
| US-8278457-B2 | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110105533-A1 | Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof | PFIZER INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105533-A1 | Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof | STS, SULT2A1, SULT1A1 | RCE1 1770/4885MMP3 3858/4885HTR2A 1626/4885 |
| US-20120322823-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | RCE1 1770/4885MMP3 3858/4885HTR2A 1626/4885 |
| US-20140323502-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | RCE1 1770/4885MMP3 3858/4885HTR2A 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.